Measurement of controlled attenuation parameter: a surrogate marker of hepatic steatosis in patients of nonalcoholic fatty liver disease on lifestyle modification – a prospective follow-up study

Jayanta Paul, Raj Vigna Venugopal, Lorance Peter, Kula Naresh Kumar Shetty and Mohit P Shetti

ABSTRACT – Background – Liver biopsy is a gold standard method for hepatic steatosis assessment. However, liver biopsy is an invasive and painful procedure and can cause severe complications therefore it cannot be frequently used in case of follow-up of patients. Non-invasive assessment of steatosis and fibrosis is of growing relevance in non-alcoholic fatty liver disease (NAFLD). To evaluate hepatic steatosis, transient elastography with controlled attenuation parameter (CAP) measurement is an option nowadays. Objective – Aim of this study is to evaluate role of measurement of controlled attenuation parameter, a surrogate marker of hepatic steatosis in patients of nonalcoholic fatty liver disease on lifestyle modification.

Methods – In this study, initially 37 participants were included who were followed up after 6 months with transient elastography, blood biochemical tests and anthropometric measurements. The results were analyzed by Multivariate linear regression analysis and paired samples \textit{t}-test (Dependent \textit{t}-test) with 95% confidence interval. Correlation is calculated by Pearson correlation coefficients. Results – Mean CAP value for assessing hepatic steatosis during 1st consultation (278.57±49.13 dB/m) was significantly improved (\(P=0.01\)) after 6 months of lifestyle modification (252.91±62.02 dB/m). Only fasting blood sugar (\(P=0.008\)), weight (\(P=0.000\)), body mass index (BMI) (\(P=0.000\)) showed significant positive correlation with CAP. Only BMI (\(P=0.034\)) and weight (\(P=0.035\)) were the independent predictor of CAP value in NAFLD patients. Conclusion – Lifestyle modification improves the hepatic steatosis, and CAP can be used to detect the improvement of hepatic steatosis during follow-up in patients with NAFLD on lifestyle modification. There is no relation between CAP and Fibroscan score in NAFLD patients. Only BMI and weight can predict CAP value independently.

HEADINGS – Fatty liver. Biopsy, adverse effects. Elasticity imaging techniques, utilization. Life style.

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is increasingly diagnosed worldwide and is the most prevalent chronic liver disease in both developed and developing countries ranging from simple steatosis and steatohepatitis to fibrosis and long-term complications like cirrhosis and hepatocellular carcinoma\(^{1,2,3}\). Therefore, early assessment of extent of hepatic steatosis and monitor during therapy are important. The gold standard method to detect hepatic steatosis and steatohepatitis is liver biopsy but it has some limitations like sampling errors, intra- and inter-observer variability, invasiveness of the procedure and major complications like bleeding\(^{4}\). To avoid these limitations of liver biopsy and to quantify the hepatic steatosis, controlled attenuation parameter (CAP) being implemented on Fibroscan has been introduced as a non-invasive method in order to evaluate both steatosis and fibrosis simultaneously\(^{5}\), and is reported to be highly sensitive in detecting low grade steatosis as fat deposition \(\geq10\%\)^{6}. Several biopsy-controlled clinical studies showed that CAP can accurately detect and quantify hepatic steatosis\(^{7,8,9}\). Lifestyle modification including weight loss and increased physical activity is vital in managing NAFLD patients irrespective of their underlying liver histology. There is no research using CAP values to assess effect of lifestyle modification on hepatic steatosis in Indian population with non-alcoholic fatty liver disease.

Therefore, the aim of this study is to evaluate role of measurement of controlled attenuation parameter, a surrogate marker of hepatic steatosis in patients of nonalcoholic fatty liver disease on lifestyle modification.

METHODS

Study design and study population

In this prospective follow up study, initially there were 45 NAFLD patients diagnosed by ultrasonography (USG) abdomen, blood report and history included, but only 37 participants came after 6 months of their 1st consultation. Out of 37 patients, 2 patients were excluded from our study, since they did not follow the life style modification as advised to them. So our study was concentrated on 35 patients (FIGURE 1).
**Exclusion criteria**

U/L in males and 19 U/L in females of normal]. The upper limit of normal for ALT was defined as 35.

**Inclusion criteria**

Age of the patient was >18 years, Elevated liver enzyme [alanine aminotransferase (ALT) levels >1.5 times of the upper limit of normal]. The upper limit of normal for ALT was defined as 35 U/L in males and 19 U/L in females(10), fatty liver in USG abdomen.

**Exclusion criteria**

Alcohol consumption, smoking, medications & toxins caus-
ing fatty liver, autoimmun & inflammatory disease, malnutri-
tion, total parenteral nutrition, severe weight loss, viral hepatitis and metabolic liver disease (Wilson’s disease, hemochromatosis, etc.), ascites, cirrhosis, chronic illness: e.g. tuberculosis, renal failure, pregnancy, gastroplasty / bowel resection / bowel bypass surgery.

**Study site:** Department of Gastroenterology, Manipal Hospital, Bangalore, India.

**Study duration:** 1 year and 3 months. Follow up evaluation (2nd consultation) has been done after 6 months of first consultation.

**Methodology**

**Anthropometry measurements**

- Weight in kilograms, height in meters.
- Body mass index (BMI): BMI was calculated with the using of weight in kilograms/height in meters:\[
  \text{BMI} = \frac{\text{Weight (kg)}}{\text{Height (m)}^2}.
\]
- Blood pressure: hypertension was diagnosed when a patient had received medicine for hypertension or had systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg after taking 5 min rest(11).

**Others biochemical tests:** blood sample was collected after an overnight fast of >12 hours.

- Fasting blood sugar.
- Total cholesterol: patients who used cholesterol lowering medication or had a total serum cholesterol level ≥200 mg/dL were classified as having hypercholesterolemia(12).
- Serum fasting insulin.
- HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) = \{Fasting insulin (µU/mL) × [Fasting glucose (mmol/L) / 22.5]\} was calculated to assess the insulin resistance. A HOMA-IR value of ≥2.5 is taken as an indicator of insulin resistance (IR) in adults(13).
- Alanine aminotransferase.

**CAP and liver stiffness measurement**

The Fibroscan equipped with the M probe placing on the skin between the ribs over the right lobe of the liver was used to capture both CAP and liver stiffness measurement (LSM) values simultaneously. CAP values and LSM values were expressed in units of decibels per meter (dB/m) and kilopascal (kPa) respectively.

During measurement, patients were in supine position with the right arm in abduction. At least 10 valid measurements were obtained in one particular site from each participant. A success rate of ≥60% and the ratio of the interquartile range (IQR) of liver stiffness to the median (IQR/M) ≤30% were considered reliable and used for the final analysis(14).

Steatosis was graded depending on CAP value according to a previous study(15): S1≥238 dB/m, S2≥260 dB/m, and S3≥293 dB/m.

**Trans-abdominal ultrasonography**

Fatty liver was diagnosed based on standard criteria from trans-abdominal ultrasonography (USG) findings using a 3.5 MHz probe. The USG findings of fatty liver are hepatorenal contrast, liver brightness, and vascular blurring(15), hyper echogenic liver tissue with fine, tightly packed echoes(16). Trans abdominal ultrasonography was done by single consultant radiologist who was not aware of the subjects’ clinical details or laboratory findings.
Physical activity

In this study, physical exercise was assessed by self-reported questionnaires which include questions about duration, frequency, and intensity of exercise.

We advised to do regular moderate physical activity which is defined as doing physical exercise of at least moderate intensity at least 3 days per week, for at least 45 minutes each time (The University of California San Diego approach) for an uninterrupted duration of 6 months.

Physical activity of moderate intensity is defined by World Health Organization as requiring a metabolic equivalent task (MET) score of 3.0–6.0 and a typical activity of moderate intensity is “brisk” walking at 5.6 km/h on a flat surface requiring 3.8 MET(17).

Metabolic equivalent of functional capacity(18); 3 MET: brisk walking; 4 MET: raking leaves, gardening, jogging; 5 MET: climbing 1 flight of stairs, dancing, bicycling, badminton, swimming; 6 MET: plying golf, carrying clubs.

Diet

Caloric intake was restricted to 25-30 kcals/kg/day of ideal body weight(19) in our study population. Patients were advised to avoid saturated fats, simple carbohydrates, sweetened drinks, ‘fast food diet’ and monitored after 6 months with self-reported questionnaires.

Statistical analysis

The Statistical Package for Social Sciences (SPSS) is used for statistical analysis. The results were analyzed by multivariate linear regression analysis and paired samples t-test (Dependent t-test) with 95% confidence interval. Correlation is calculated by Pearson correlation coefficients. A probability value (P) below 0.05 is considered significant. Data were expressed as means ± standard deviation (SD).

RESULTS

Demographic and clinical data

Out of 35 participants, 24 (68.57%) participants were male and 11 (31.43%) participants were female. The mean age of our study population was 34.03±6.28 years. Mean age of male and female participants were 34.25±6.47 years and 33.54±6.14 years respectively.

Ten (28.57%) and four (11.42%) participants during their 1st consultation and 2nd consultation were insulin resistance respectively.

Overall mean BMI of study population at the time of 1st consultation was 27.58±2.56 kg/m² but Mean BMI of male participants (26.95±2.29 kg/m²) was lower than the female participants (28.95±2.70 kg/m²) (FIGURE 2).

During follow up visit after 6 months of lifestyle modification, overall BMI of study populations was 25.65±2.31 kg/m² but BMI of male participants and female participants were 25.27±2.26 kg/m² and 26.46±2.31kg/m² respectively (FIGURE 2).

Out of 35 NAFLD patients, 10 (28.57%) and 8 (28.85%) were hypertensive during their 1st consultation and 2nd consultation respectively. During 1st visit, 17 (48.7%) participants and during 2nd consultation, 11 (31.42%) participants had hypercholesterolemia (FIGURE 3).

Effects of 6 months lifestyle modification

Mean HOMA-IR value for detection of insulin resistance of our study population during 1st and 2nd visit were 2.13±0.63 and 1.75±0.45 respectively (P=0.001) (FIGURE 3).

Mean Fibroscan value for liver stiffness during 1st consultation and after 6 months of lifestyle modification were 8.35±0.73 kPa and 7.92±0.76 kPa respectively (P=0.019).

Mean ALT value before and after 6 months of lifestyle modification were 99.57±14.37 U/L and 68.51±14.70 U/L respectively (P=<0.001) (FIGURE 3).

Mean CAP value for assessing hepatic steatosis during 1st consultation (278.57±49.13 dB/m) was significantly improved (P=0.03) after 6 months of lifestyle modification (252.91±62.02 dB/m) (TABLE 1) (FIGURE 4).
TABLE 1. Demographic characters and clinical data of study population before and after of 6 months lifestyle modification

<table>
<thead>
<tr>
<th>Demographic character and clinical data</th>
<th>At the time of first consultation</th>
<th>After 6 months of lifestyle modification</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years)</td>
<td>34.03 ± 6.28</td>
<td>32.45 ± 6.49</td>
<td>-----</td>
</tr>
<tr>
<td>Mean weight (kg)</td>
<td>82.42 ± 9.27</td>
<td>74.92 ± 8.60</td>
<td>-----</td>
</tr>
<tr>
<td>Number of patients</td>
<td>N = 35</td>
<td>N = 30</td>
<td>-----</td>
</tr>
<tr>
<td>Male</td>
<td>N = 24 (68.57%)</td>
<td>N = 20 (66.67%)</td>
<td>-----</td>
</tr>
<tr>
<td>Female</td>
<td>N = 11 (31.43%)</td>
<td>N = 10 (33.33%)</td>
<td>-----</td>
</tr>
<tr>
<td>Insulin resistance (HOMA-IR &gt;2.5)</td>
<td>N = 10 (28.57%)</td>
<td>N = 4 (11.42%)</td>
<td>-----</td>
</tr>
<tr>
<td>HOMA-IR value</td>
<td>2.13 ± 0.65</td>
<td>1.75 ± 0.45</td>
<td>0.001</td>
</tr>
<tr>
<td>Hypertension</td>
<td>N = 10 (28.57%)</td>
<td>N = 8 (22.85%)</td>
<td>-----</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>N = 17 (48.7%)</td>
<td>N = 11 (31.43%)</td>
<td>-----</td>
</tr>
<tr>
<td>Mean BMI (kg/m²)</td>
<td>27.58 ± 2.56</td>
<td>25.65 ± 2.31</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mean BMI of Male (kg/m²)</td>
<td>26.95 ± 2.29</td>
<td>25.27 ± 2.26</td>
<td>-----</td>
</tr>
<tr>
<td>Mean BMI of Female (kg/m²)</td>
<td>28.95 ± 2.70</td>
<td>26.46 ± 2.31</td>
<td>-----</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>99.57 ± 14.37</td>
<td>68.51 ± 14.70</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FBS</td>
<td>96.28 ± 10.59</td>
<td>89.71 ± 9.08</td>
<td>0.002</td>
</tr>
<tr>
<td>Fibroscan value (kPa)</td>
<td>8.35 ± 0.73</td>
<td>7.92 ± 0.76</td>
<td>0.019</td>
</tr>
<tr>
<td>CAP (dB/m)</td>
<td>278.57 ± 49.13</td>
<td>252.91 ± 62.02</td>
<td>0.03</td>
</tr>
<tr>
<td>Hepatic steatosis (S0)*</td>
<td>N = 7 (20%)</td>
<td>N = 15 (42.85%)</td>
<td>-----</td>
</tr>
<tr>
<td>Hepatic steatosis (S1)*</td>
<td>N = 5 (14.28%)</td>
<td>N = 4 (11.43%)</td>
<td>-----</td>
</tr>
<tr>
<td>Hepatic steatosis (S2)*</td>
<td>N = 12 (34.29%)</td>
<td>N = 8 (22.86%)</td>
<td>-----</td>
</tr>
<tr>
<td>Hepatic steatosis (S3)*</td>
<td>N = 11 (31.43%)</td>
<td>N = 8 (22.86%)</td>
<td>-----</td>
</tr>
</tbody>
</table>


FIGURE 4. Controlled attenuation parameter (CAP) value and percentages of study population with different stages of hepatic steatosis before (Series 1) and after (Series 2) lifestyle modification.

Correlations of CAP with different parameters during first consultation

Fibroscan (P=0.91), ALT (P=0.62), height (P=0.17), systolic blood pressure (P=0.53), diastolic blood pressure (P=0.90), serum fasting insulin (P=0.37), HOMA IR value (P=0.08), Total cholesterol (P=0.15) and age (P=0.16) were not significantly correlated with CAP. But fasting blood sugar (P=0.008), weight (P=0.000), BMI (P=0.000) showed significant positive correlation with CAP (TABLE 2) (FIGURE 5).

TABLE 2. Correlation between the controlled attenuation parameter and clinical parameters

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Correlation</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibroscan</td>
<td>-0.018</td>
<td>0.91</td>
</tr>
<tr>
<td>ALT</td>
<td>0.085</td>
<td>0.62</td>
</tr>
<tr>
<td>Height</td>
<td>0.232</td>
<td>0.17</td>
</tr>
<tr>
<td>Weight</td>
<td>0.733</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI</td>
<td>0.754</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>0.110</td>
<td>0.53</td>
</tr>
<tr>
<td>Diastolic blood pressure</td>
<td>-0.021</td>
<td>0.90</td>
</tr>
<tr>
<td>Fasting blood sugar</td>
<td>0.442</td>
<td>0.008</td>
</tr>
<tr>
<td>Fasting Insulin</td>
<td>0.154</td>
<td>0.37</td>
</tr>
<tr>
<td>HOMA IR value</td>
<td>0.297</td>
<td>0.08</td>
</tr>
<tr>
<td>Age</td>
<td>0.239</td>
<td>0.16</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>0.247</td>
<td>0.15</td>
</tr>
</tbody>
</table>

ALT: alanine aminotransferase; HOMA IR: Homeostatic model assessment of insulin resistance; BMI: body mass index. Correlation is significant at P<0.05 level.
Measurement of controlled attenuation parameter: a surrogate marker of hepatic steatosis in patients of nonalcoholic fatty liver disease on lifestyle modification – a prospective follow-up study

Hepatic steatosis, particularly due to NAFLD, is common and increasing in prevalence. In around 20% patients, hepatic steatosis may progress to non-alcoholic steatohepatitis, cirrhosis, end-stage liver disease and hepatocellular carcinoma.

Liver biopsy, the gold standard for assessing hepatic steatosis, is rarely performed due to the trauma, sampling error, complications and imperfect reproducibility. Recently hepatic fat quantification by non-invasive methods has gained importance for the diagnosis and monitoring of hepatic steatosis. Although for detecting hepatic steatosis, ultrasonography is a useful technique but it cannot be used for grading of hepatic steatosis.

Serological scoring methods such as the SteatoTest, the Fatty Liver Index (FLI) and the Hepatic Steatosis Index (HSI) include a number of biochemical markers and/or anthropometric parameters that have been developed in the last decade to diagnose hepatic steatosis. The FLI is an independent predictor of mortality. Similarly, the HSI, which includes the alanine transaminase/ aspartate transaminase ratio, BMI, gender and diabetes, is associated with the presence and severity of steatosis on ultrasound.

Ultrasound is the most commonly used imaging method to detect hepatic steatosis, which is recognized by a diffuse increase in echogenicity. It is accepted as an initial tool for fatty liver as it is non-invasive, non-ionizing, inexpensive and widely available. Limitations of ultrasound of liver include its low sensitivity for mild steatosis (<30%) and inability to quantify hepatic fat and the potential for extensive fibrosis to increase liver echogenicity.

Other abdominal imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy are expensive, not widely available, absence of standardization, and exposure to ionizing radiation in CT scan. CAP, a recently used novel and noninvasive method for both diagnosing and quantifying hepatic steatosis as it has accuracy, convenience, and economic feasibility. CAP values did not appear to be influenced by inflammation, fibrosis or etiology.

As far as my knowledge perhaps this is the first study where the effect of lifestyle modification (including diet restriction and moderately intense physical exercise) on CAP in patients with NAFLD has been studied.

In our study, we have seen that after 6 months of lifestyle modification CAP value, a surrogate marker of hepatic steatosis has improved significantly. All the previous studies involving liver biopsy for the detection of hepatic steatosis in NAFLD patients has showed that lifestyle modification has helped to reduce the hepatic steatosis significantly. Same result was also found in another study using abdominal ultrasonography for detection of hepatic steatosis in NAFLD patients.

The mean BMI in our cohort was 27.58 ± 2.56 kg/m² and 80% of patients had steatosis during first consultation. In the other studies, mean BMI was 24-25 kg/m² and 31%-58% had significant steatosis.

Significant improvement in fasting blood sugar and HOMA-IR index were noted in our study. These findings are compatible with those of previous reports.

Like the other previous studies, in our present study it has been demonstrated that there is reduction in ALT level in NAFLD patients after 6 months of lifestyle modification.

In this study, there is no correlation between CAP value and Fibroscan score in NAFLD patients.

**DISCUSSION**

Multivariate linear regression analysis of CAP with other parameters during first consultation

Only BMI (P=0.034) and weight (P=0.035) were the independent predictor factors of CAP value (TABLE 3).

CAP value is not affected by age (P=0.35), fasting blood sugar (P=0.90), fasting insulin (P=0.98), HOMA IR (P=0.98), ALT (P=0.68) and cholesterol (P=0.11).

**TABLE 3.** Multivariate linear regression analyses between controlled attenuation parameter and different parameters during first consultation

<table>
<thead>
<tr>
<th>Parameters</th>
<th>95% CI Lower bound</th>
<th>95% CI Upper bound</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibroscan</td>
<td>-18.259</td>
<td>18.655</td>
<td>0.98</td>
</tr>
<tr>
<td>Age</td>
<td>-1.191</td>
<td>3.177</td>
<td>0.35</td>
</tr>
<tr>
<td>Weight</td>
<td>0.171</td>
<td>4.344</td>
<td>0.035</td>
</tr>
<tr>
<td>BMI</td>
<td>0.798</td>
<td>18.112</td>
<td>0.034</td>
</tr>
<tr>
<td>Fasting blood sugar</td>
<td>-6.008</td>
<td>6.827</td>
<td>0.90</td>
</tr>
<tr>
<td>Fasting insulin</td>
<td>-52.540</td>
<td>53.397</td>
<td>0.98</td>
</tr>
<tr>
<td>HOMA IR</td>
<td>-245.098</td>
<td>239.123</td>
<td>0.98</td>
</tr>
<tr>
<td>ALT</td>
<td>-1.251</td>
<td>0.826</td>
<td>0.68</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>-0.787</td>
<td>0.094</td>
<td>0.11</td>
</tr>
</tbody>
</table>

BMI: body mass index; ALT: alanine aminotransferase; HOMA IR: Homeostatic model assessment of insulin resistance; CI: confidence interval. P < 0.05 is considered as statistically significant.
CONCLUSION

Lifestyle modification improves the hepatic steatosis and CAP can be used to detect the improvement of hepatic steatosis during follow-up in patients with NAFLD on lifestyle modification. There is no correlation between CAP and Fibroscan score. CAP value is affected by weight and BMI, but age, fasting blood sugar, fasting insulin, HOMA IR value, ALT and cholesterol don’t have any effect on CAP value.

ACKNOWLEDGEMENTS

We are extremely thankful to Manipal Hospital to allow me to conduct this work. We express our gratitude to colleagues, technical and non-technical staff of Gastroenterology department, Manipal Hospital, Bangalore because without their support conducting this research work would not have been possible.

Authors’ contributions

Paul J: substantial contributions to the conception, design of the work, the acquisition, analysis, and interpretation of data for the work. Drafting the work, revising it critically for important intellectual content and Final approval of the version. Venugopal RV: design of the work, analysis, interpretation of data for the work. Peter L: design of the work, analysis, interpretation of data for the work. Shetty KNK: design of the work, analysis, interpretation of data for the work. Shetti MP: design of the work, analysis, interpretation of data for the work.

REFERENCES


Paul J, Venugopal RV, Peter L, Shetty KNK, Shetti MP. Measurement of controlled attenuation parameter: a surrogate marker of hepatic steatosis in patients of nonalcoholic fatty liver disease on lifestyle modification – a prospective follow-up study.